Seocalcitol

Identification

Name
Seocalcitol
Accession Number
DB04258  (EXPT01322)
Type
Small Molecule
Groups
Experimental, Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • (5Z,7E,22E,24E)-(1S,3R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,3,25-triol
  • 22-24-DIENE-24A,26A,27A,TRIHOMO-1ALPHA,25-DIHYDROXYVITAMIN D3
External IDs
CB-1089 / EB-1089
Categories
UNII
Q0OZ0D9223
CAS number
134404-52-7
Weight
Average: 454.6844
Monoisotopic: 454.344695338
Chemical Formula
C30H46O3
InChI Key
LVLLALCJVJNGQQ-SEODYNFXSA-N
InChI
InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/s1
IUPAC Name
(1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5E)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol
SMILES
[H]\C(\C(\[H])=C(/[H])C(O)(CC)CC)=C(\[H])[[email protected]@]([H])(C)[[email protected]@]1([H])CC[[email protected]@]2([H])\C(CCC[[email protected]]12C)=C(/[H])\C(\[H])=C1\C[[email protected]@]([H])(O)C[[email protected]]([H])(O)C1=C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UVitamin D3 receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Seocalcitol.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Seocalcitol.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Seocalcitol.Approved, Investigational, Withdrawn
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Seocalcitol.Approved
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Seocalcitol.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Seocalcitol.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Seocalcitol.Investigational
BendroflumethiazideThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Bendroflumethiazide.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Seocalcitol.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Seocalcitol.Approved
ChlorothiazideThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Chlorothiazide.Approved, Vet Approved
ChlorthalidoneThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Chlorthalidone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Seocalcitol.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Seocalcitol.Approved
CyclopenthiazideThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Cyclopenthiazide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Seocalcitol.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Seocalcitol.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Seocalcitol.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Seocalcitol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Seocalcitol.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Seocalcitol.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Seocalcitol.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Seocalcitol.Approved, Investigational
EpitizideThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Epitizide.Experimental
FingolimodSeocalcitol may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Seocalcitol.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Seocalcitol.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Seocalcitol.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Seocalcitol.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Seocalcitol.Approved, Withdrawn
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Seocalcitol.Approved
HydrochlorothiazideThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Hydroflumethiazide.Approved, Investigational
IndapamideThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Indapamide.Approved
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Seocalcitol.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Seocalcitol.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Seocalcitol.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Seocalcitol.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Seocalcitol is combined with Leflunomide.Approved, Investigational
MethyclothiazideThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Methyclothiazide.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Seocalcitol.Experimental
MetolazoneThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Metolazone.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Seocalcitol is combined with Natalizumab.Approved, Investigational
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Seocalcitol.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Seocalcitol.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Seocalcitol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Seocalcitol.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Seocalcitol.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seocalcitol.Approved, Investigational
PolythiazideThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Polythiazide.Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Seocalcitol.Experimental
QuinethazoneThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Seocalcitol is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Seocalcitol.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Seocalcitol.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Seocalcitol.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Seocalcitol.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Seocalcitol.Approved, Investigational
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Seocalcitol.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Seocalcitol.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Seocalcitol.Approved, Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Seocalcitol.Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of Seocalcitol.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Seocalcitol.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Seocalcitol.Investigational
TofacitinibSeocalcitol may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Seocalcitol.Approved, Investigational
TrichlormethiazideThe risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Trichlormethiazide.Approved, Vet Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Seocalcitol.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Seocalcitol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
20055510
PubChem Substance
46507218
ChemSpider
4450374
ChEMBL
CHEMBL1908376
HET
EB1
PDB Entries
1s0z

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedEducational/Counseling/TrainingNeoplasms, Hepatic1
Not AvailableTerminatedEducational/Counseling/TrainingNeoplasms, Hepatic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00382 mg/mLALOGPS
logP6.59ALOGPS
logP5.27ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)14.39ChemAxon
pKa (Strongest Basic)-1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity142.26 m3·mol-1ChemAxon
Polarizability56.4 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9932
Blood Brain Barrier+0.9064
Caco-2 permeable+0.7586
P-glycoprotein substrateSubstrate0.782
P-glycoprotein inhibitor INon-inhibitor0.6259
P-glycoprotein inhibitor IINon-inhibitor0.6716
Renal organic cation transporterNon-inhibitor0.8359
CYP450 2C9 substrateNon-substrate0.8427
CYP450 2D6 substrateNon-substrate0.8969
CYP450 3A4 substrateSubstrate0.7277
CYP450 1A2 substrateNon-inhibitor0.8674
CYP450 2C9 inhibitorNon-inhibitor0.8597
CYP450 2D6 inhibitorNon-inhibitor0.9287
CYP450 2C19 inhibitorNon-inhibitor0.8098
CYP450 3A4 inhibitorNon-inhibitor0.657
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5196
Ames testNon AMES toxic0.9398
CarcinogenicityNon-carcinogens0.8961
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity4.2195 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8284
hERG inhibition (predictor II)Non-inhibitor0.7689
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Vitamin D and derivatives
Direct Parent
Vitamin D and derivatives
Alternative Parents
Triterpenoids / Tertiary alcohols / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
Substituents
Triterpenoid / Tertiary alcohol / Cyclic alcohol / Secondary alcohol / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Alcohol / Aliphatic homopolycyclic compound
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Vitamin D3 and derivatives (LMST03020449)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B...
Gene Name
VDR
Uniprot ID
P11473
Uniprot Name
Vitamin D3 receptor
Molecular Weight
48288.64 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 15:25